Pfizer Inc. $PFE Shares Purchased by QSM Asset Management Ltd

QSM Asset Management Ltd grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 10.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 506,843 shares of the biopharmaceutical company’s stock after purchasing an additional 46,100 shares during the period. Pfizer accounts for 7.2% of QSM Asset Management Ltd’s portfolio, making the stock its 4th biggest position. QSM Asset Management Ltd’s holdings in Pfizer were worth $12,620,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Horizon Financial Services LLC grew its position in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the last quarter. Grey Fox Wealth Advisors LLC bought a new position in Pfizer in the third quarter worth about $29,000. Howard Hughes Medical Institute acquired a new position in Pfizer in the second quarter valued at approximately $30,000. Darwin Wealth Management LLC acquired a new position in Pfizer in the second quarter valued at approximately $32,000. Finally, True Wealth Design LLC grew its holdings in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Market optimism around Pfizer’s once‑monthly GLP‑1/weight‑loss candidate and coverage by high‑profile commentators has driven short‑term buying interest — investors are revisiting Pfizer’s positioning in the obesity/GLP‑1 market. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Longer‑term bullish commentary and retail coverage argue Pfizer’s diversified portfolio, pipeline and ability to pivot (including GLP‑1 work) make it an attractive buy for patient investors. This kind of coverage can sustain inflows beyond short‑term headlines. Prediction: Buying Pfizer Stock Today Could Set You Up for Life
• Positive Sentiment: Inclusion on lists of large‑cap stocks with high dividends highlights Pfizer’s income appeal; dividend support can attract conservative and yield‑seeking investors amid growth uncertainty. Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Spike in search and retail attention (tracked by Zacks) signals higher visibility and trading volume; increased attention can amplify moves in either direction depending on upcoming catalysts. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Consensus analyst rating remains a “Hold” (mixed buy/hold/sell split), reflecting balanced views on near‑term growth vs. pipeline uncertainty — this limits the likelihood of broad upgrades unless clinical or commercial news surprises to the upside. Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: Competitive moves from rivals — notably Eli Lilly’s large AI‑enabled drug discovery deal — underline accelerating competition and faster innovation cycles in diabetes/weight‑loss and other areas, a risk to Pfizer’s market share and margin outlook over time. Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PFE shares. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a report on Thursday, February 12th. Bank of America lowered their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Guggenheim raised their target price on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.19.

Pfizer Stock Up 2.6%

Shares of Pfizer stock opened at $27.75 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The business’s fifty day moving average price is $26.88 and its two-hundred day moving average price is $25.72. The company has a market capitalization of $157.80 billion, a P/E ratio of 20.41 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period last year, the company earned $0.63 earnings per share. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.